Three out of four patients with metastatic breast cancer would be candidates for targeted therapy

by archynewsy
0 comment

It is possible to increase the detectionof potentially treatable genomic alterations in patients with metastatic breast cancer. This is shown by the HOPE study, by the SOLTI group, which was presented at the congress held by the European Society of Medical Oncology (ESMO 2023) in Madrid.

The data presented by Tomás Pascual, researcher of the aforementioned work, oncologist at the Hospital Clínic of Barcelona and scientific director of SOLTI at ESMO 2023 and which correspond to the analysis of more than 50% of the 600 (356 so far) patients included in the study , show that 75% of the patients analyzed present genomic alterations in their tumor and, therefore, they can have potential targeted treatment.

Before carrying out the aforementioned study, only 15% of women knew about these alterations, which shows that thanks to the screening carried out at HOPE, it has been multiplied by 5 the detection of alterations.

This is the first national clinical trial – whose inclusion has been led by patients with metastatic breast cancer- which demonstrates the benefit of offering access to tumor sequencing techniques and thus extending the precision oncology throughout the territory..

By using sequencing tests to detect mutations or biomarkers, both in blood as in tumor tissue carried out in the context of HOPE, the number of patients who now have information that could help them guide their oncological treatment has multiplied by 5.

Related Posts

Leave a Comment